Investment Analysts’ Updated EPS Estimates for January, 23rd (ADMS, BSET, BWXT, CECE, CLSD, CRWS, CSOD, CUDA, CVLT, EGHT)
Adamas Pharmaceuticals (NASDAQ:ADMS) had its buy rating reaffirmed by analysts at Mizuho. The firm currently has a $48.00 target price on the stock. The analysts wrote, “We think the timing of the financing (in front of early Gocovri commercial updates) is ideal, and should allow shares to rebound quickly. There is an additional $12.75M greenshoe option that we expect to be filled as well. The company indicated it had $176.4M in cash/investments on its balance sheet as of December 31, 2017, up from $130.7M in cash at the end of 3Q:17, and also received a $65M payment from Healthcare Royalty Partners in 4Q:17. We estimate that Adamas therefore used ~$19.3M in cash in 4Q:17 and should have ~$270M in cash after the equity financing (with no additional financing needs this year). Because we believe that Adamas is a likely takeout target during a period of increased M&A activity and higher CNS valuations, it is possible that this could be its last financing event. We continue to view ADMS as our top pick in 2018, and reiterate our Buy rating.””
Bassett Furniture Industries (NASDAQ:BSET) was downgraded by analysts at Zacks Investment Research from a buy rating to a strong sell rating. According to Zacks, “Bassett Furniture Industries, Inc. is a leading manufacturer and marketer of high quality, mid-priced home furnishings. With over one hundred and thirty Bassett Furniture Direct stores, Bassett has leveraged its brand name in furniture with a network of licensed and Company-owned stores that focus on providing consumers with a friendly and professional environment for buying furniture and accessories. The Company continues to sell its products to other retailers, in addition to the Company’s dedicated retail store program. Bassett’s retail strategy promotes affordable custom-built furniture that is ready for delivery in the home within thirty days. The stores also feature the latest on-trend furniture styles, more than one thousand upholstery fabrics, free in-home design visits, and coordinated decorating accessories. “
CECO Environmental (NASDAQ:CECE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CECO ENVIRONMENTAL CORP. manufactures and sells, primarily in the United States, of fiber bed mist eliminators to the chemical, printing, plating, power generation, food processing, waste incineration and textile industries. “
Clearside Biomedical (NASDAQ:CLSD) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. “
Crown Crafts (NASDAQ:CRWS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Crown Crafts, Inc. operates, both directly and indirectly through its subsidiaries, in two principal business segments within the textile industry: Adult Home Furnishing and Juvenile Products, and Infant Products. Adult Home Furnishing and Juvenile Products consists of Bedroom Products, Throws and Decorative Home Accessories, and Juvenile Products. The Infant Products segment consists of infant bedding, bibs, infant soft goods and accessories. “
Cornerstone OnDemand (NASDAQ:CSOD) had its hold rating reaffirmed by analysts at Piper Jaffray Companies. The firm currently has a $44.00 price target on the stock.
Barracuda Networks (NYSE:CUDA) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Barracuda Networks, Inc. is engaged in designing and delivering security and storage solutions. Its products span three distinct markets, including: 1) content security, 2) networking and application delivery and 3) data storage, protection and disaster recovery. It offers cloud-connected solutions that help its customers address security threats, enhance network performance, and protect and store their data. Barracuda Networks, Inc. is headquartered in Campbell, California. “
CommVault Systems (NASDAQ:CVLT) had its buy rating reissued by analysts at Mizuho. Mizuho currently has a $75.00 price target on the stock. The analysts wrote, “We expect license revenue of around $83mm (+15% Y/Y or +5% sequentially), largely in-line with consensus. Total revenue could print around $180-185mm (+8-11% Y/Y or +7-10% sequentially) on incremental flow through of maintenance revenue post pricing realignment and contribution from recent license bookings. Profitability estimates of 13% are in-line with guidance and seem reasonable. CFFO estimates of 18% margin could be slightly on the high side; however, maintenance renewal bookings should help. Click here for our detailed preview and model.””
8X8 (NASDAQ:EGHT) had its hold rating reaffirmed by analysts at William Blair. The analysts wrote, “We remain cautious on 8×8 shares despite investor exuberance related to valuation discrepancy (relative to a public peer) and recently aroused M&A speculation. In our view , the stock appears ahead of itself heading into the print, in light of ongoing sales- and-marketing restructuring, which is likely to take several quarters to execute upon. In the meantime, we expect pressure on operating margin (due to aggressive hiring) and sales bookings (due to salesforce rotation and involuntary churn). While we believe 8×8 is making the right changes to emerge from this transformation as a better-executing and more-focused growth company , we would need to see evidence of the turnaround first manifesting itself in the improved bookings growth rates (in either SMB or midmarket/enterprise segment) and sales productivity metrics.””
Halliburton (NYSE:HAL) had its hold rating reaffirmed by analysts at Cowen Inc. They currently have a $60.00 target price on the stock.
Huntington Bancshares (NASDAQ:HBAN) had its buy rating reaffirmed by analysts at Vining Sparks. They currently have a $19.00 price target on the stock. The analysts wrote, “Continued strong earnings momentum along with a meaningfully higher return-on-tangible common equity should allow HBAN to continue to trade at around a 15x price-to-earnings multiple. This valuation coupled with continued double-digit EPS growth and a 2.7% dividend yield should produce a total shareholder return of over 20%.””
Gartner (NYSE:IT) had its hold rating reaffirmed by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $130.00 price target on the stock.
Leggett & Platt (NYSE:LEG) had its hold rating reiterated by analysts at Piper Jaffray Companies. They currently have a $48.00 price target on the stock.
Rush Enterprises (NASDAQ:RUSHA) had its hold rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $51.00 target price on the stock.
Texas Instruments (NASDAQ:TXN) had its buy rating reaffirmed by analysts at Drexel Hamilton. Drexel Hamilton currently has a $110.00 price target on the stock.
Vertex Pharmaceuticals (NASDAQ:VRTX) had its buy rating reiterated by analysts at Bank of America Corp. Bank of America Corp currently has a $180.00 target price on the stock.
Voyager Therapeutics (NASDAQ:VYGR) had its buy rating reaffirmed by analysts at Canaccord Genuity. They currently have a $26.00 target price on the stock. The analysts wrote, “We note, however, that the IND acceptance is a key step that allows VYGR to start its pivotal Phase 2-3 trial program per plan in 2Q18. VYGR has several potential catalysts coming up over the course of 2018 (see Table 1 on page 2 for details). Specifically, in our view, longer-term Phase 1b data (readouts over 2018) could favorably support the continued development of VY-AADC in advanced PD, and we are reiterating our BUY ahead of the availability of these data.””
Webster Financial (NYSE:WBS) had its hold rating reaffirmed by analysts at Piper Jaffray Companies. They currently have a $56.00 target price on the stock.
Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.